Cargando…

Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B

BACKGROUND: Visceral leishmaniasis (VL), a potentially fatal disease, is most prevalent in the Indian subcontinent, East Africa and South America. Since the conventional antileishmanial drugs have many limitations we evaluated a new ergosterol rich liposomal amphotericin B formulation, KALSOME™10 fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asad, Mohammad, Bhattacharya, Pradyot, Banerjee, Antara, Ali, Nahid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411769/ https://www.ncbi.nlm.nih.gov/pubmed/25884796 http://dx.doi.org/10.1186/s12879-015-0928-6

Ejemplares similares

Apoptosis-like cell death in Leishmania donovani treated with KalsomeTM10, a new liposomal amphotericin B
por: Shadab, Md., et al.
Publicado: (2017)

Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh
por: Lucero, Emiliano, et al.
Publicado: (2015)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

A Curative Immune Profile One Week after Treatment of Indian Kala-Azar Patients Predicts Success with a Short-Course Liposomal Amphotericin B Therapy
por: Mondal, Smriti, et al.
Publicado: (2010)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
por: Ren, Danfeng, et al.
Publicado: (2021)

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2017)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

Liposomal amphotericin B as a treatment for human leishmaniasis
por: Balasegaram, Manica, et al.
Publicado: (2012)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
por: Ubals, Maria, et al.
Publicado: (2021)

Amphotericin B Formulations and Other Drugs for Visceral Leishmaniasis
por: Berman, Jonathan
Publicado: (2015)

First case of pulmonary tuberculosis and visceral leishmaniasis coinfection successfully treated with antituberculosis drug and liposomal amphotericin B
por: Hasnain, Md Golam, et al.
Publicado: (2014)

Disseminated tegumentary leishmaniasis refractory to liposomal amphotericin B treatment
por: Borges, Ana Flávia, et al.
Publicado: (2021)

Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
por: Tamiru, Aschalew, et al.
Publicado: (2016)

Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis
por: Ravindran, Rajesh, et al.
Publicado: (2010)

Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Evaluation of Nephroprotective and Immunomodulatory Activities of Antioxidants in Combination with Cisplatin against Murine Visceral Leishmaniasis
por: Sharma, Meenakshi, et al.
Publicado: (2012)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome(®) and AmBisome(®) in murine cutaneous leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Introducing Single Dose Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis in Rural Bangladesh: Feasibility and Acceptance to Patients and Health Staff
por: Maintz, Eva-Maria, et al.
Publicado: (2014)

A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure
por: Eichenberger, Anna, et al.
Publicado: (2017)

Efficacy of an Immunotherapy Combining Immunogenic Chimeric Protein Plus Adjuvant and Amphotericin B against Murine Visceral Leishmaniasis
por: Vale, Danniele L., et al.
Publicado: (2023)

Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis
por: Lestner, Jodi, et al.
Publicado: (2017)

Reversible Ototoxicity: A Rare Adverse Reaction of Liposomal Amphotericin-B Used for the Treatment of Antimony-Resistant Visceral Leishmaniasis in an Elderly Male
por: Das, PC, et al.
Publicado: (2014)

Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome)
por: Burza, Sakib, et al.
Publicado: (2014)

Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral Leishmaniasis: A Randomized, Open-Label Study
por: Sundar, Shyam, et al.
Publicado: (2014)

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea
por: Guery, Romain, et al.
Publicado: (2017)

Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
por: Jaafari, Mahmoud Reza, et al.
Publicado: (2019)

Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis
por: Shahnaz, Gul, et al.
Publicado: (2017)

Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India
por: Fakiola, Michaela, et al.
Publicado: (2019)

Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Edwards, Tansy, et al.
Publicado: (2011)

Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis
por: Parvez, Shabi, et al.
Publicado: (2020)

962. Cutaneous Leishmaniasis: Investigating Skin Drug Levels to Optimize Liposomal Amphotericin Dosing
por: Aronson, Naomi E, et al.
Publicado: (2018)

Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
por: Hasnain, Md Golam, et al.
Publicado: (2018)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
Publicado: (2014)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
Publicado: (2014)

1554. Nebulized Liposomal Amphotericin B for Treatment of Murine Pulmonary Mucormycosis
por: Sandoval, Adilene, et al.
Publicado: (2019)

Immunity to Visceral Leishmaniasis
por: Ali, Nahid, et al.
Publicado: (2012)

Rhinophyma-Like Cutaneous Leishmaniasis due to Leishmania aethiopica Treated Successfully with Liposomal Amphotericin B
por: Kirchberger, Michael Constantin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7gru13d6juoumofnc1ia38q7o0